Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.38
-5.73 (-2.73%)
AAPL  266.71
+2.13 (0.81%)
AMD  194.68
-5.47 (-2.74%)
BAC  51.19
-1.88 (-3.53%)
GOOG  310.82
-4.08 (-1.30%)
META  636.53
-19.13 (-2.92%)
MSFT  383.56
-13.67 (-3.44%)
NVDA  190.31
+0.50 (0.26%)
ORCL  139.73
-8.35 (-5.64%)
TSLA  394.57
-17.25 (-4.19%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.